



(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)

A61K 31/00 (2006.01) A61P 35/02 (2006.01)

A61K 39/395 (2006.01) A61K 47/68 (2017.01)

A61K 47/06 (2006.01) A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2020/031067

(22) International Filing Date:

01 May 2020 (01.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/843,226 03 May 2019 (03.05.2019) US

(71) Applicant: **SUTRO BIOPHARMA, INC.** [US/US]; 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US).

(72) Inventors: **LEE, John**; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US). **STAFFORD, Ryan**; c/o Sutro Biopharma, Inc., 310

Utah Avenue, Suite 150, South San Francisco, CA 94080 (US). **YAM, Alice**; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US). **LI, Xiaofan**; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US). **YU, Abigail**; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US). **GAKHAL, Amandeep**; c/o Sutro Biopharma, Inc., 310 Utah Avenue, Suite 150, South San Francisco, CA 94080 (US).

(74) Agent: **GEORGE, Nikolaos, C.** et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: ANTI-BCMA ANTIBODY CONJUGATE, COMPOSITIONS COMPRISING THE SAME, AND METHODS OF MAKING AND USING THE SAME




FIG. 1

(57) Abstract: The present disclosure relates to antibody conjugates with binding specificity for BCMA (BCMA) and its isoforms and homologs, and compositions comprising the antibody conjugates, including pharmaceutical compositions. Also provided are methods of producing the antibody conjugates and compositions as well as methods of using the antibody conjugates and compositions, such as in therapeutic and diagnostic methods.



SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))